On July 17, 2026, Tatva Chintan Pharma Chem Limited reported its consolidated financial results for the quarter ending June 30, 2026, as per the exchange filings.
The company posted a total income of ₹169.84 crore and net profit of ₹15.98 crore for the the quarter ending June 30, 2026.
Tatva Chintan Pharma Chem Limited saw a 43.9% year-on-year increase in total income, reaching ₹169.84 crore, compared to ₹118.02 crore in the same quarter last year. Quarter-on-quarter, the income rose 26.9% from ₹133.80 crore in March 2026.
Net profit for the quarter surged 140.3% year-on-year to ₹15.98 crore from ₹6.65 crore a year ago and increased 54.8% quarter-on-quarter from ₹10.32 crore in March 2026.
For the fiscal year 2026, Tatva Chintan Pharma Chem Limited reported a total income of ₹509.41 crore. The net profit for the same period stood at ₹42.05 crore.
These figures highlight the company's robust financial performance and growth trajectory over the past year.
In a strategic move to enhance production capabilities, Tatva Chintan has approved the establishment of a new greenfield manufacturing unit at Dahej - III, Gujarat.
This facility will feature an aggregated reactor capacity of 344 kilolitres (KL) and is projected to be executed within 21 months.
The expansion requires an estimated investment of ₹200 crore, which will be funded through a combination of internal accruals and debt.
Read More: Avantel Share Price in Focus; Bags ₹20.81 Crore SATCOM Services Order From L&T!
The board has re-appointed Mr. Chintan Nitinkumar Shah as Managing Director for a 3-year term starting February 1, 2027.
Mr. Ajaykumar Mansukhlal Patel and Mr. Shekhar Rasiklal Somani have also been re-appointed as Whole-time Directors for the same duration.
These leaders, who are promoters and founding members, will continue to play a pivotal role in the company's operations, subject to retirement by rotation.
As of July 20, 2026, at 10:17 AM, Tatva Chintan Pharma Chem share price on NSE was trading at ₹1,713.70, up by 20.00% from the previous closing price.
Tatva Chintan Pharma Chem Limited's Q1 2026 results show a 43.9% YoY income rise to ₹169.84 crore and a 140.3% YoY net profit increase to ₹15.98 crore. The company plans a ₹200 crore greenfield expansion at Dahej - III, Gujarat.
For daily market updates and regular stock market news in Hindi, stay tuned to Angel One's share market news in Hindi.
Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.
Published on: Jul 20, 2026, 10:45 AM IST
Team Angel One
We're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
